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BACKGROUND: Height and body mass index (BMI) are associated with higher ovarian cancer risk in the general population, but
whether such associations exist among BRCA1/2 mutation carriers is unknown.
METHODS:We applied a Mendelian randomisation approach to examine height/BMI with ovarian cancer risk using the Consortium
of Investigators for the Modifiers of BRCA1/2 (CIMBA) data set, comprising 14,676 BRCA1 and 7912 BRCA2 mutation carriers, with
2923 ovarian cancer cases. We created a height genetic score (height-GS) using 586 height-associated variants and a BMI genetic
score (BMI-GS) using 93 BMI-associated variants. Associations were assessed using weighted Cox models.
RESULTS: Observed height was not associated with ovarian cancer risk (hazard ratio [HR]: 1.07 per 10-cm increase in height, 95%
confidence interval [CI]: 0.94–1.23). Height-GS showed similar results (HR= 1.02, 95% CI: 0.85–1.23). Higher BMI was significantly
associated with increased risk in premenopausal women with HR= 1.25 (95% CI: 1.06–1.48) and HR= 1.59 (95% CI: 1.08–2.33) per
5-kg/m2 increase in observed and genetically determined BMI, respectively. No association was found for postmenopausal women.
Interaction between menopausal status and BMI was significant (Pinteraction < 0.05).
CONCLUSION: Our observation of a positive association between BMI and ovarian cancer risk in premenopausal BRCA1/2 mutation
carriers is consistent with findings in the general population.
British Journal of Cancer (2019) 121:180–192; https://doi.org/10.1038/s41416-019-0492-8
BACKGROUND
Ovarian cancer is the fifth leading cause of cancer deaths in US
women, due to its typically advanced stage at presentation.1,2
Furthermore, unlike breast or colorectal cancer, there is no proven
screening method for ovarian cancer to identify early disease and
initiate treatment to improve survival.3,4 Family history, oral
contraceptive use, parity, body mass index (BMI), and genetic
variants are potentially useful in estimating lifetime risk.1 In
particular, inherited BRCA1 and BRCA2 mutations are associated
with increased lifetime risk of ovarian cancer and account for
~10–15% of overall disease incidence.5–7 However, among
mutation carriers, age at diagnosis is variable. Penetrance of
BRCA1/2 mutations is likely modified by other genetic variants and
lifestyle or reproductive factors.8,9 Investigation of these factors
could aid in implementation of strategies to reduce ovarian cancer
risk among mutation carriers.
Both height and BMI are quantitative traits with substantial
genetic bases. In recent genome-wide association studies (GWAS),
numerous genetic variants were found to be associated with these
traits.10,11 In the general population, both height and BMI appear
to be positively but inconsistently associated with risk of ovarian
cancer.12–14 Previous studies also showed that the association
between BMI and ovarian cancer was stronger in premenopausal
women.12,15,16 Because of differences in age at onset and tumour
histology/grade, risk factors for ovarian cancer might be different
for BRCA1/2 mutation carriers than women in the general
population.17 Only one case–control study, with 469 ovarian
cancer cases, has examined anthropometric measurements in
BRCA1/2 mutation carriers and found that neither height nor BMI
were related to ovarian cancer risk.18 Larger, adequately powered
studies are needed to assess whether a relationship between
either height or BMI and ovarian cancer risk exists for BRCA1/2
mutation carriers, and whether the direction of association is
concordant with that in the general population.
Mendelian randomisation (MR) methods use genetic markers
associated with a trait as an instrumental variable (IV) to assess
their potential relationship with a disease outcome.19–21 Com-
pared to traditional epidemiologic approaches, MR can reduce
biases such as reverse causation and residual confounding, which
can interfere with causal interpretations. However, the MR
approach requires that the genetic variants are associated with
the exposure, the variants are not or only weakly associated with
confounding factors in the causal pathway, and the variants only
affect disease risk through the exposure (i.e. absence of pleiotropic
effects).20,21 To the degree that these assumptions are met, the MR
approach can strengthen the evidence for a causal relationship
between exposure and disease.
Herein, using traditional epidemiologic and MR methods, we
conducted analyses of height and BMI and their association with
ovarian cancer risk in the Consortium of Investigators for the
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Modifiers of BRCA1/2 (CIMBA) with 22,588 participants. We
examined heterogeneity of these associations with respect to
the mutation carried (BRCA1 vs BRCA2), menopausal status,
tumour histology, and tumour grade.
METHODS
Characteristics of the CIMBA consortium and information on
specific genotyping protocols are provided in Supplementary
Methods and were described previously.22–24
Selection of genetic variants
From the latest publications of the Genetic Investigation of
Anthropometric Traits, we identified single-nucleotide polymorph-
isms (SNPs) associated with height or BMI at genome-wide
significance level (P < 5 × 10−8).11,25 SNPs with low imputation
quality (<0.5) were excluded, leaving 586 SNPs for height and 93
for BMI. Supplementary Tables 1 and 2 provide additional details
on these SNPs.
Statistical analysis
Calculation of the height and BMI genetic scores (GS) was
described in detail previously.24 Briefly, we calculated the
weighted sums of all of the height- and BMI-associated variants
under additive models, which do not include interactions between
variants. Namely, we used the formulas: Height GS ¼P586
i¼1 βXGiSNPi and BMI GS ¼
P93
i¼1 βXGiSNP, where βXGi is the
literature-reported per-allele magnitude of association of the ith
SNP for height and BMI, respectively. A scaling factor was
calculated by regressing each GS against its respective trait
among non-case carriers. The corresponding regression coeffi-
cients were β0 (intercept= 165.455) and β1 (slope= 5.217) for
height and β0 (22.607) and β1 (5.523) for BMI. In the present study,
BMI-GS was scaled to BMI at the date of questionnaire, rather than
BMI at age 18 years, as previous GWAS were based on BMI
measurements in middle-aged adults.
We subsequently modelled each scaled GS against ovarian
cancer risk using weighted Cox models. Our primary outcome of
interest was ovarian cancer diagnosis, with individuals censored
for breast cancer diagnosis, risk-reducing bilateral salpingo-
oophorectomy, death, or end of follow-up, whichever occurred
first. Owing to the study design of CIMBA, weights in the model
were applied for cases and non-cases based on previously
observed incidence of ovarian cancer in BRCA1/2 carriers.26,27
We applied a robust sandwich variance-estimation approach to
the risk estimates to account for non-independence among
multiple carriers per family. In addition, we performed subgroup
analyses by BRCA1/2 mutations and menopausal status. Meno-
pausal status was defined as a time-varying covariate, coded as
premenopausal from birth until age at natural menopause or
bilateral salpingo-oophorectomy. For individuals with missing age
at menopause, we imputed the age as 50 years. Imputing missing
age at menopause as 46 years did not materially change the
results. The mean and median ages at natural menopause in this
population were 46 and 48 years, respectively. All analyses were
adjusted for the first eight principal components (to account for
ethnicity and population stratification), birth cohort, and country
of enrolment. Additional analyses assessed the associations of
height and BMI with ovarian cancer subgroups by histological
type (serous vs. non-serous) and by tumour grade (well or
moderately differentiated tumours vs. poorly or undifferentiated).
In addition, phenotype associations with each individual height
and BMI variant were assessed and pooled using inverse variance-
weighted meta-analysis. The individual associations were obtained
by first extracting βXGi for each SNP i, which represents the per-
allele magnitude of association with height or BMI from previous
GWAS. Next, we calculated βYGi and SE βYGið Þ using multivariate-
adjusted weighted Cox models for each SNP using the CIMBA
data, where ovarian cancer risk is predicted by genotype G (with
G= 0, 1, 2 for the allele corresponding to greater height or BMI),
principal components, birth cohort, BRCA mutation, and country of
enrolment. The overall causal association (βYX) is calculated using
inverse-variance weighted estimate of each variant’s effect:
βYX ¼
P
i
βXGiβYGiSEðβYGiÞ2P
i
β2XGiSEðβYGiÞ2
. Standard error was estimated as SEYX ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1P
i
β2XGiSEðβYGiÞ2
q
using the Burgess’s method.19,28 Egger’s test was
used to assess for possible pleiotropic effects of the variants (i.e.
whether variants influence the outcome through other pathways),
to ensure that this assumption held.29
Finally, in participants with available data on height and BMI, we
conducted a formal IV analysis using the method of two-stage
residual inclusion regression.30 In stage one, observed height or
BMI was regressed against the corresponding GS, principal
components, birth cohort, country, and mutation status. In the
second stage, we used a Cox model to fit ovarian cancer risk
against height or BMI, birth cohort, country, mutation status, and
residuals from stage one. Variance estimates were obtained
through 10,000 boot-straps (see details in Supplementary
Methods). In these individuals, we also analysed the association
between observed measurements of height or BMI and ovarian
cancer risk using weighted Cox models, adjusted for established
ovarian cancer risk factors, including birth cohort, menopausal
status, age at menarche (years), and parity (continuous). The BMI
values used were obtained at the date of questionnaire, usually
close to the date of genetic testing and recalled for BMI at age
18 years.
In models with menopausal status as time-varying variable, the
test for heterogeneity by menopausal status was essentially a test
of the proportional hazards assumption. All analyses were
performed using SAS 9.4 (SAS Institute, Cary, NC) and Stata 14.0
(StataCorp, College Station, TX). A two-sided P-value < 0.05 was
considered statistically significant unless stated otherwise.
RESULTS
Demographic and clinical characteristics
Characteristics for the 22,588 individuals in the CIMBA consortium,
comprising 14,676 BRCA1 and 7912 BRCA2 mutation carriers, are
shown in Table 1. We documented 2923 women with ovarian
cancer (BRCA1: 2319; BRCA2: 604). Compared with non-cases,
participants who developed ovarian cancer were more often
parous women, were younger at first live birth, and were from
earlier birth cohorts. At the date of questionnaire/interview, height
measurement was available for 7657 participants and BMI
measurement for 7516 participants. Most tumours for BRCA1/2
mutation carriers were invasive, of serous, poorly, or undiffer-
entiated grade, and stages 3 or 4 at diagnosis, characteristics
which are consistent with prior reports.31
Observed and predicted height on risk of ovarian cancer
In the survival modelling of ovarian cancer risk, age was used as
the underlying timescale and the numbers of individuals retained
in the analysis were 20535, 14647, 7375, and 2832 at ages 30, 40,
50, and 60 years, respectively, suggesting that statistical power for
the late age is limited. After adjustment for birth cohort, country of
enrolment, mutation, menopausal status, and principal compo-
nents, a nonsignificant association was found for observed height
and ovarian cancer risk (hazard ratio (HR)= 1.07 per 10-cm
increase, 95% confidence interval (CI): 0.94–1.23, P= 0.31)
(Table 2). We found broadly consistent associations of height in
both BRCA1 and BRCA2 mutation carriers by menopausal status
and by tumour histological type and grade.
The height GS was significantly associated with height in all
participants, in ovarian cancer cases, and in non-case participants
(all P < 10−24) (Supplementary Table 3). Overall, approximately
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13.4% of the variation in height was explained by the height GS.
Besides height, we found weaker associations between the height
GS and body weight and age at menarche.
In MR analysis, height GS had a nonsignificant positive
association with ovarian cancer risk, HR= 1.02 per 10-cm increase
in genetically predicted height, 95% CI: 0.85–1.23, P= 0.82
(Table 3). We found similar associations by subgroups of mutation,
menopausal status, and tumour grade.
Combining the effects of all 586 height-associated variants
using inverse-variance weighted meta-analysis, we obtained
similar findings (HR= 1.02, 95% CI: 0.83–1.26, P= 0.83) (λ). Among
the SNPs that were combined, there was a low degree of
heterogeneity (I2= 0%). Examining small-study effects using
Egger’s test did not suggest likely pleiotropic effects. In the two-
stage residual inclusion analysis, the estimated relative risk was
larger though with wide CIs, which overlapped with those derived
using other methods (HR= 1.20, 95% CI: 0.86–1.69, P= 0.29).
Observed and predicted BMI on risk of ovarian cancer
After multivariable adjustment, we found a nonsignificant positive
association between BMI at the date of questionnaire completion
and ovarian cancer risk, HR= 1.04 per 5-kg/m2 increase in BMI,
95% CI: 0.95–1.14, P= 0.42 (Table 4). In a pre-specified analysis,
the association between BMI and ovarian cancer risk was stronger
in premenopausal women (HR= 1.25, 95% CI: 1.06–1.48; P=
0.009), whereas no association was found in postmenopausal
women (HR= 0.98, 95% CI: 0.88–1.10), with significant interaction
(P= 0.02). We found that BMI was a significant predictor of non-
serous ovarian cancer risk (HR= 1.25, 95% CI: 1.06–1.49) but not
for serous ovarian cancer (HR= 0.98, 95% CI: 0.84–1.15).
Similar to BMI at the date of questionnaire completion, we
detected a significant interaction of BMI in young adulthood and
menopausal status (P= 0.01), with a stronger association for
premenopausal women (HR= 1.34, 95% CI: 0.97–1.84) compared
with postmenopausal women (HR= 0.82, 95% CI: 0.65–1.04).
BMI-GS was strongly associated with BMI at both the date of
questionnaire completion and young adulthood (Supplementary
Table 4). Overall, the BMI-GS explained 2.6% of the variation in BMI
at the date of questionnaire completion and 1.7% of the variation
in young adulthood BMI. We found associations between the BMI-
GS and height and age at menarche, though the strength of the
association was weaker than the association with BMI.
In the entire consortium, the BMI-GS had a nonsignificant positive
association with ovarian cancer risk with a HR= 1.10 per 5-kg/m2 of
genetically predicted BMI, 95% CI: 0.86–1.42, P= 0.44 (Table 5). We
found heterogeneity by menopausal status (P= 0.006). BMI-GS was
positively associated with ovarian cancer risk in premenopausal
Table 1. Baseline characteristics of participants in the CIMBA
consortium with genotype information
Variable Ovarian cancer
cases, N= 2923
Non-cases,
N= 19,665
P valueb
Mutation carrier status <0.0001
BRCA1 2319 (79.3) 12,357 (62.8)
BRCA2 604 (20.7) 7308 (37.2)
Year of birth,
median (IQR)
1948
(1940, 1955)
1960
(1951, 1969)
<0.0001
Age at diagnosis or
censoring, years (mean
± SD)
52.5 ± 9.8 44.7 ± 12.4 <0.0001
Ethnicity, n (%) 0.07
Caucasian, not
otherwise specified
2060 (89.7) 13,613 (88.4)
Ashkenazi Jewish 237 (10.3) 1780 (11.6)
Height in cm, n 784 6873
Mean ± SD 163.2 ± 6.5 164.8 ± 6.9 <0.0001
Weight at baselinea in
kg, n
780 6789
Mean ± SD 69.0 ± 14.6 68.5 ± 14.1 0.32
Body mass index at
baselinea in kg/m2, n
772 6744
Mean ± SD 25.9 ± 5.3 25.2 ± 5.1 0.0002
Weight in early
adulthood in kg, n
536 4,912
Mean ± SD 56.5 ± 8.3 57.9 ± 9.5 0.0007
Body mass index in early
adulthood in kg/m2, n
536 4881
Mean ± SD 21.2 ± 3.0 21.3 ± 3.3 0.43
Age at menarche in
years, n
771 6688
Mean ± SD 13.0 ± 1.5 13.0 ± 1.5 0.90
Parous, n (%) <0.0001
Yes 805 (88.3) 5790 (77.4)
No 107 (11.7) 1692 (22.6)
Age at first live birth in
years, n
735 5555
Mean ± SD 24.4 ± 4.5 25.4 ± 4.9 <0.0001
Menopausal status, n (%) <0.0001
Premenopausal 112 (11.5) 3816 (51.1)
Postmenopausal 863 (88.5) 3654 (48.9)
Age at menopause,
years (mean ± SD)
46.8 ± 5.7 44.7 ± 6.1 <0.0001
Tumour behaviour, n (%)
Invasive 1228 (99.2)
Borderline 10 (0.8)
Tumour histotype, n (%)
Serous 892 (67.9)
Mucinous 20 (1.5)
Endometrioid 141 (10.7)
Clear cell 17 (1.3)
Other 243 (18.5)
Tumour grade, n (%)
Well differentiated 43 (4.6)
Moderately
differentiated
196 (21.0)
Table 1 continued
Variable Ovarian cancer
cases, N= 2923
Non-cases,
N= 19,665
P valueb
Poorly/
undifferentiated
696 (74.4)
Tumour stage, n (%)
Borderline 2 (0.3)
Stage 1 121 (16.4)
Stage 2 93 (12.6)
Stage 3 412 (55.7)
Stage 4 112 (15.1)
CIMBA Consortium of Investigators for the Modifiers of BRCA1/2, IQR
interquartile range, SD standard deviation
aReported at the date of questionnaire
bP values for comparing cases and non-cases were calculated from logistic
regression models with robust sandwich variance estimator
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women (HR= 1.59, 95% CI: 1.08–2.33) but not in postmenopausal
women (HR= 0.80, 95% CI: 0.58–1.11). BMI-GS also tended to be
more associated with non-serous (HR= 1.60, 95% CI: 0.83–3.08) than
serous tumours (HR= 0.92, 95% CI: 0.59–1.43).
We found similar results when we statistically combined the
associations of the 93 BMI-associated variants, with an overall
HR= 1.12, 95% CI: 0.86–1.46. Heterogeneity was low (I2= 15.9%),
indicating a low likelihood of pleiotropic associations. Using the two-
stage residual inclusion approach, we found a generally similar
association (HR= 1.37, 95% CI: 0.84–2.24, P= 0.21).
Individual SNPs and ovarian cancer risk
We found 22 height-associated and 4 BMI-associated SNPs that
were nominally associated with ovarian cancer risk (P < 0.05;
Table 6). None of these SNPs were significantly associated with
ovarian cancer risk after correcting for multiple testing. We cross-
checked these identified SNPs with the most up-to-date list of
ovarian cancer susceptibility SNPs and did not find any overlaps.32
DISCUSSION
Using data from a large international consortium of BRCA1/2
mutation carriers, we found no statistically significant association
between height and ovarian cancer risk. Interestingly, we
observed interactions between BMI (both observed and geneti-
cally predicted) and menopausal status on ovarian cancer risk,
with increasing BMI associated with increased risk in premeno-
pausal but not in postmenopausal women.
Our finding of a positive association between BMI and overall
ovarian cancer risk in BRCA1 and BRCA2 mutation carriers is
corroborated by several prior studies in the general
population.12,14,15,33 One MR analysis using 77 BMI-associated
SNPs, conducted in the general population, found that each
1-standard deviation (SD) increment in genetically-predicted adult
BMI corresponded to an odds ratio (OR) of 1.35 (95% CI:
1.05–1.72).34 We found that 5-kg/m2 (about 1 SD) increment in
genetically predicted BMI was associated with an HR= 1.10 (95%
CI: 0.86–1.42) in mutation carriers. However, the association of BMI
with ovarian cancer risk is likely to vary by menopausal status. In
the general population, significant differential association of BMI
with ovarian cancer risk by menopausal status has been found in
some studies15,16,35,36 but not in others.12,37 A pooled analysis of
47 epidemiologic studies with 25,157 ovarian cancer cases
showed that the relative risk per 5-kg/m2 increase in BMI was
1.12 (95% CI: 1.07–1.17) in premenopausal women and 1.08 (95%
CI: 1.04–1.12) in postmenopausal women.12 The largest single
cohort study, with 3686 ovarian cancer cases, found that the HR
per 5-kg/m2 increase in BMI was 1.21 (99% CI: 1.09–1.33) in
premenopausal and 1.07 (99% CI: 1.02–1.12) in postmenopausal
women.15 An MR analysis conducted in the general population
also observed stronger associations for non-high-grade serous
carcinomas in premenopausal women (OR= 1.62, 95% CI:
0.88–3.01) compared with postmenopausal hormone replacement
therapy (HRT) users (OR= 1.26, 95% CI: 0.57–2.82) and post-
menopausal HRT non-users (OR= 1.17, 95% CI: 0.61–2.24), though
no formal statistical tests examining heterogeneity were per-
formed.14 Similarly, we found in BRCA1/2 mutation carriers that
5-kg/m2 increment in genetically predicted BMI was associated
with an HR= 1.59 (95% CI: 1.08–2.33) for premenopausal ovarian
cancer and an HR= 0.80 (95% CI: 0.58-1.11) for postmenopausal
ovarian cancer. Studies that have not demonstrated significant
variation by menopausal status tended to show that the positive
association between BMI and ovarian cancer risk was primarily
among those who had never used HRT.12 Taken together, our
results and previous literature are suggestive that higher BMI may
increase ovarian cancer risk in premenopausal women but not in
postmenopausal women.
In addition, several studies that had sufficient numbers of cases to
evaluate the relationship between BMI and ovarian cancer risk by
histologic subtype have shown significant heterogeneity. Observa-
tional studies in the Ovarian Cancer Cohort Consortium found
stronger associations between BMI and endometrioid (OR= 1.17 per
5-kg/m2, 95% CI: 1.11–1.23) or mucinous ovarian cancer (OR= 1.19,
95% CI: 1.06–1.32) but no association with serous ovarian cancer
(OR= 0.98, 95% CI: 0.94–1.02).16 A more recent MR analysis in the
same consortium using a genetic score comprised of 87 SNPs
showed that a genetically predicted BMI had a stronger association
with endometrioid (OR= 1.17, 95% CI: 0.87–1.59) or mucinous
ovarian cancer (OR= 1.18, 95% CI: 0.84–1.67) than high-grade
Table 2. Association of height and ovarian cancer risk using observed
height among 7657 participants
N/events HR (95% CI) P value
Per 10 cm increase in observed height
All participants (confounding adjustment sequentially)
Adjusted for principal
components
7657/784 1.12
(0.97–1.29)
0.12
Additionally adjusted for
country
7657/784 1.15
(1.00–1.32)
0.06
Additionally adjusted for
birth cohort
7657/784 1.05
(0.91–1.21)
0.53
Additionally adjusted for
mutation status
7657/784 1.06
(0.92–1.22)
0.42
Additionally adjusted for
menopausal status
7657/784 1.07
(0.94–1.23)
0.31
Additionally adjusted for
parity and age at menarche
7090/724 1.09
(0.94–1.26)
0.24
By mutation statusa
BRCA1 carrier 4502/552 1.07
(0.91–1.24)
0.42
BRCA2 carrier 3155/232 1.11
(0.85–1.45)
0.44
Pinteraction 0.64
By menopausal statusb
Premenopausal 7657/105 1.02
(0.72–1.42)
0.93
Postmenopausal 4328/679 1.09
(0.94–1.26)
0.27
Pinteraction 0.71
By tumour subtypec
Serous 7360/319 1.07
(0.87–1.31)
0.52
Non-serousd 7360/168 1.30
(1.01–1.68)
0.045
Phet 0.24
By tumour gradec
Well or moderately
differentiated
7252/111 1.12
(0.83–1.52)
0.46
Poorly/undifferentiated 7252/268 1.15
(0.93–1.43)
0.19
Phet 0.89
HR hazard ratio, CI confidence interval
aAdjusted for principal components, birth cohort, country of enrolment,
and menopausal status in weighted Cox model
bAdjusted for principal components, mutation status, birth cohort, and
country of enrolment
cAdjusted for principal components, birth cohort, country of enrolment,
mutation status, and menopausal status
dIncludes endometrioid, mucinous, clear cell, and other histologic types
Bolded line refers to the model corresponding to our main results
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serous cancer (OR= 1.06, 95% CI: 0.89–1.27), though the 95% CIs for
these estimates were largely overlapping.14 Consistent with findings
in the general population, our study in BRCA1/2 mutation carriers
showed that BMI was positively associated with non-serous ovarian
cancer (HR= 1.25 per 5-kg/m2, 95% CI: 1.06–1.49 in observed BMI
and HR= 1.60, 95% CI: 0.83–3.08, per 5-kg/m2 in genetically
predicted BMI), of which endometrioid is a major subtype. Of note,
obesity is an established risk factor for endometrial cancer.38
However, subsequent studies with greater number of cases of
different ovarian cancer subtypes are needed to assess whether the
effect of obesity truly differs by tumour subtype.
Our finding of a nonsignificant positive association between
height and ovarian cancer risk is also consistent with prior
epidemiological studies in the general population.12,37,39 In the
general population, 5-cm increment in height was associated with
a 7% increase (95% CI: 5–9%) in ovarian cancer risk,12 and 5-cm
increment in genetically predicted height was associated with a
6% (95% CI: 1–11%) increase in ovarian cancer risk.39 The
associations for observed height did not differ significantly
between ovarian histological types,2,12 while genetically predicted
height had a stronger association with clear cell (OR= 1.20,
95% CI: 1.04–1.38) or low-grade/borderline serous ovarian cancers
(OR= 1.15, 95% CI: 1.01–1.30) compared to high-grade serous
(OR= 1.05, 95% CI: 0.99–1.11).39 We did not find statistically
significant heterogeneity by histology in our study of mutation
carriers, though point estimates varied across histology.
Several biological mechanisms potentially explain the associa-
tions observed in our study. Overweight/obese women are more
Table 3. Association of height and ovarian cancer risk among 22,588 participants in CIMBA per 10-cm increase in genetically predicted height
N/events HR (95% CI) P value Heterogeneity (I2)
Height GSa
All participants (confounding adjustment sequentially)
Adjusted for principal components 22,588/2923 0.99 (0.82–1.19) 0.89
Additionally adjusted for country 22,588/2923 0.97 (0.81–1.17) 0.77
Additionally adjusted for birth cohort 22,588/2923 0.98 (0.82–1.18) 0.83
Additionally adjusted for mutation status 22,588/2923 1.02 (0.85–1.22) 0.13
Additionally adjusted for menopausal status 22,588/2923 1.02 (0.85–1.23) 0.82
By mutation statusb
BRCA1 carrier 14,676/2319 1.02 (0.83–1.25) 0.87
BRCA2 carrier 7912/604 1.04 (0.68–1.57) 0.87
Pinteraction 0.99
By menopausal statusc
Premenopausal 22,588/967 0.96 (0.73–1.26) 0.77
Postmenopausal 9219/1955 1.08 (0.85–1.38) 0.52
Pinteraction 0.50
By tumour subtyped
Serous 20,978/892 1.36 (0.97–1.90) 0.08
Non-serous 20,978/421 0.95 (0.58–1.56) 0.84
Phet 0.25
By tumour graded
Well or moderately differentiated 20,600/239 1.63 (0.86–3.09) 0.14
Poorly/undifferentiated 20,600/696 1.20 (0.82–1.74) 0.35
Phet 0.42
Meta-analysis methode
All participants 22,588/2923 1.02 (0.83–1.26) 0.83 0.0%
BRCA1 carrier 14,676/2319 1.02 (0.81–1.28) 0.89 0.0%
BRCA2 carrier 7912/604 1.05 (0.67–1.66) 0.82 7.0%
Pinteraction 0.89
Two-stage residual inclusion methodf
All participants 7657/784 1.20 (0.86–1.69) 0.29
BRCA1 carrier 4502/552 1.40 (0.94–2.10) 0.10
BRCA2 carrier 3155/232 0.93 (0.49–1.74) 0.81
HR hazard ratio, CI confidence interval, CIMBA Consortium of Investigators for the Modifiers of BRCA1/2, GS genetic score
aHeight genetic score combining 586 height-associated single-nucleotide polymorphisms (SNPs)
bAdjusted for principal components, birth cohort, country of enrolment, and menopausal status in weighted Cox model
cAdjusted for principal components, mutation status, birth cohort, and country of enrolment
dAdjusted for principal components, mutation status, menopausal status, birth cohort, and country of enrolment
eHRs were calculated using inverse-variance meta-analysis and re-scaled to the corresponding units by calculating the height measurements per z-score
among controls. Effect estimates for ovarian cancer for each SNP were calculated from weighted Cox model adjusting for principal components, birth cohort,
country of enrolment, menopausal status, and mutation status
fAnalysis was performed among 7657 participants with measured height
Bolded line refers to the model corresponding to our main results
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likely to have anovulatory cycles and fertility issues, particularly
when caused by polycystic ovarian syndrome (PCOS), and thus
have an increased risk of ovarian cancer.40,41 The association of
PCOS with ovarian cancer risk was mainly confined to premeno-
pausal women.42 Some studies have suggested that BRCA1/2
mutation carriers may have subclinical ovarian insufficiency, which
could mediate the relationship between obesity-related infertility
and increased ovarian cancer risk.43 Obesity itself also creates a
proinflammatory state and adipocyte-secreted inflammatory
markers have been implicated in ovarian cancer development.44
Circulating levels of oestradiol, androgen, and progesterone have
also been implicated in the risk of ovarian cancer.45,46 One study in
BRCA1/2 mutation carriers showed higher oestradiol levels during
each menstrual cycle compared with non-carriers, supporting the
potential role of sex hormones in ovarian tumorigenesis in this
population.47 Obese premenopausal women tend to have lower
Table 4. Association of body mass index (BMI) and ovarian cancer risk using observed BMI
N/events HR (95% CI) P value
Per 5 kg/m2 increase in BMI at date of questionnaire
All participants (confounding adjustment sequentially)
Adjusted for principal components 7516/772 1.00 (0.90–1.10) 0.96
Additionally adjusted for country 7516/772 0.99 (0.90–1.09) 0.84
Additionally adjusted for birth cohort 7516/772 1.02 (0.93–1.12) 0.72
Additionally adjusted for mutation status 7516/772 1.06 (0.96–1.16) 0.26
Additionally adjusted for menopausal status 7516/772 1.04 (0.95–1.14) 0.42
Additionally adjusted for parity and age at menarche 6964/715 1.04 (0.94–1.14) 0.48
By mutation statusa
BRCA1 carrier 4401/543 1.06 (0.95–1.17) 0.31
BRCA2 carrier 3115/229 0.96 (0.81–1.15) 0.67
Pinteraction 0.35
By menopausal statusb
Premenopausal 7516/102 1.25 (1.06–1.48) 0.009
Postmenopausal 4257/670 0.98 (0.88–1.10) 0.78
Pinteraction 0.02
By tumour subtypec
Serous 7223/312 0.98 (0.84–1.15) 0.83
Non-serousd 7223/167 1.25 (1.06–1.49) 0.01
Phet 0.04
By tumour gradec
Well or moderately differentiated 7252/109 1.05 (0.84–1.32) 0.65
Poorly/undifferentiated 7252/268 0.95 (0.82–1.11) 0.54
Phet 0.47
Per 5 kg/m2 increase in BMI in young adulthood
All participants (confounding adjustment sequentially)
Unadjusted 5417/536 0.86 (0.69–1.07) 0.17
Adjusted for country 5417/536 0.86 (0.69–1.08) 0.19
Additionally adjusted for birth cohort 5417/536 0.87 (0.70–1.08) 0.21
Additionally adjusted for mutation status 5417/536 0.91 (0.73–1.13) 0.39
Additionally adjusted for menopausal status 5417/536 0.93 (0.76–1.16) 0.53
Additionally adjusted for parity and age at menarche 5210/516 0.92 (0.74–1.14) 0.42
By mutation statusa
BRCA1 carrier 3134/380 0.92 (0.71–1.18) 0.50
BRCA2 carrier 2283/156 1.00 (0.74–1.36) 0.99
Pinteraction 0.73
By menopausal statusb
Premenopausal 5417/67 1.34 (0.97–1.84) 0.07
Postmenopausal 3094/469 0.82 (0.65–1.04) 0.11
Pinteraction 0.01
HR hazard ratio, CI confidence interval
aAdjusted for principal components, birth cohort, country of enrolment, and menopausal status in weighted Cox model
bAdjusted for principal components, mutation status, birth cohort, and country of enrolment
cAdjusted for principal components, birth cohort, country of enrolment, mutation status, and menopausal status
dIncludes endometrioid, mucinous, clear cell, and other histological types
Bolded lines refer to the model corresponding to our main results
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circulating levels of progesterone compared with normal weight
women.48 Higher progesterone levels may reduce ovarian cancer
risk, through upregulation of p53, leading to tumour cell
apoptosis.46,49–51 Taken together, these pathways may explain
the association of higher BMI with premenopausal ovarian cancer
risk. In addition, height has been associated with higher levels of
circulating insulin-like growth factor-1 (IGF-1),52,53 a pathway that
has been implicated in tumour transformation and may exert
antiapoptotic and mitogenic effects.54,55 Moreover, BRCA1 may
directly interact with the IGF-1 pathway to mediate cancer risk.56
Our study has several strengths, including large sample size,
genetic scores utilising most identified height and BMI variants,
several MR methods, and consistent findings between observed
and genetically predicted phenotypes. Several limitations of our
study should be considered. First, even with a large sample size,
the CIs for most risk estimates were wide, which limits inferences
about causation. While both the height- and BMI-GS were clearly
associated with their respective traits, they were only able to
explain 13.4% and 2.6% of the variation, respectively. This reduced
the statistical precision of our risk estimates. During the prepara-
tion of our manuscript, a new genome-wide meta-analysis57 found
a substantial number of new genetic loci related to height and BMI,
increasing the amount of variation that could be explained for
these two traits to 24.6% and 6.0%, respectively, although the
variation that could be explained when examining these SNPs in a
validation cohort was 14.0% and 2.3%. This is comparable to the
Table 5. Association of body mass index genetic score (BMI-GS) and ovarian cancer risk among 22,588 participants in CIMBA, per 5 kg/m2 increase in
genetically predicted BMI
Breast cancer group N/events HR (95% CI) P value Heterogeneity (I2)
BMI-GSa
All participants (confounding adjustment sequentially)
Adjusted for principal components 22,588/2923 1.12 (0.87–1.45) 0.37
Additionally adjusted for country 22,588/2923 1.11 (0.86–1.44) 0.41
Additionally adjusted for birth cohort 22,588/2923 1.12 (0.87–1.45) 0.36
Additionally adjusted for mutation status 22,588/2923 1.11 (0.86–1.42) 0.43
Additionally adjusted for menopausal status 22,588/2923 1.10 (0.86–1.42) 0.44
By mutation statusb
BRCA1 carrier 14,676/2319 1.16 (0.88–1.53) 0.31
BRCA2 carrier 7912/604 0.81 (0.46–1.43) 0.46
Pinteraction 0.27
By menopausal statusc
Premenopausal 22,588/967 1.59 (1.08–2.33) 0.02
Postmenopausal 9219/1955 0.80 (0.58–1.11) 0.18
Pinteraction 0.006
By tumour subtyped
Serous 20,978/892 0.92 (0.59–1.43) 0.71
Non-serous 20,978/421 1.60 (0.83–3.08) 0.16
Phet 0.17
By tumour graded
Well or moderately differentiated 20,600/239 1.20 (0.52–2.75) 0.67
Poorly/undifferentiated 20,600/696 0.74 (0.45–1.21) 0.23
Phet 0.33
Meta-analysis methode
All participants 22,588/2923 1.12 (0.86–1.46) 0.39 15.9%
BRCA1 carrier 14,676/2319 1.18 (0.88–1.57) 0.26 17.2%
BRCA2 carrier 7912/604 0.80 (0.45–1.43) 0.45 0.0%
Pinteraction 0.24
Two-stage residual inclusion methodf
All participants 7516/772 1.37 (0.84–2.24) 0.21
BRCA1 carrier 4401/543 1.24 (0.67–2.27) 0.49
BRCA2 carrier 3115/229 1.57 (0.67–3.66) 0.30
HR hazard ratio, CI confidence interval, CIMBA Consortium of Investigators for the Modifiers of BRCA1/2
aBMI-GS was constructed by combining 93 BMI-associated single-nucleotide polymorphisms (SNPs)
bAdjusted for principal components, birth cohort, country of enrolment, and menopausal status in weighted Cox model
cAdjusted for principal components, mutation status, birth cohort, and country of enrolment
dAdjusted for principal components, mutation status, menopausal status, birth cohort, and country of enrolment
eHazard ratios were calculated using inverse-variance meta-analysis and re-scaled to the corresponding units by calculating the height measurements per z-
score among controls. Effect estimates for ovarian cancer for each SNP were calculated from weighted Cox model adjusting for principal components, birth
cohort, country of enrolment, menopausal status, and mutation status
fAnalysis was performed among 7516 participants with measured BMI
Bolded lines refer to the model corresponding to our main results
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amount of variation that could be explained using the set of
genetic variants in our study. Including these additional SNPs may
be able to improve the precision of our estimates for both height
and BMI. Moreover, the inclusion of rare variants to strengthen the
height and BMI genetic instruments should also be considered in
future studies.58 Our study did not explicitly examine whether
adding height or BMI (either observed or genetically predicted) to
existing polygenic risk scores for ovarian cancer could further
refine risk prediction. Histology was only available in a subset of
ovarian cancer patients, which limits our capacity to understand
subtype-specific effects of BMI and height. Our study only included
women of European ancestry, which may preclude generalisation
to women of other racial/ethnic groups.
In summary, our study suggests that higher BMI may be causally
associated with ovarian cancer risk in BRCA1/2 carriers, possibly
more so for premenopausal women. BMI could be used to identify
premenopausal women at elevated risk of ovarian cancer. Our
finding of a stronger association between BMI and non-serous
ovarian cancer warrants confirmation in future studies.
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